With our deep understanding of local healthcare systems, we can support innovative global biotech and pharma companies to have a significant footprint in the complex markets of Central and Eastern Europe in compliance with the highest industry standards. We strongly believe that all patients should have equal opportunities and access to the best available treatment options. Our 400 global team members are united in responsibility to support them on their journey. Our advantages: • Full commercialization through a single point of contact and delivery • Deep understanding of local healthcare systems • Direct local presence through our companies • Highest standards of ethics and compliance matching that of our partners Medis is a member of World Orphan Drug Alliance (WODA). WODA is a global alliance of full-service regional distributors. WODA's multi-territorial platform provides an alternative for pharma and biotech companies seeking a one-stop solution and comprehensive support for their products, ranging from named patient programs to full commercialization. WODA covers 76 countries in the following regions: • Central and Eastern Europe (Medis) • Greater China region (RareStone Group) • Greece, Cyprus, Malta (Path Pharma) • Israel (CTS) • Latin America (OrphanDC) • Middle East, North Africa & Turkey (Vector Pharma) • Russia & CIS region (Orpharm) • Switzerland (EffRx Pharmaceuticals) Major Partners: Besins, Biogen, Biotest, Johnson&Johnson, Merz, Mundipharma, PTC Therapeutics, Pierre Fabre, Santen, UCB, Pleuran, Ricerfarma, UP Medi Europa, Abbott, Aesculap, Asahi Medical, B. Braun, Cytosorbents, Biotest, Zimmer MedizinSysteme Get in touch with us: business.development@medis.com T: +386 1 600 22 42